WO2012004653A1 - Method for inhibition of nf-kb gene expression - Google Patents
Method for inhibition of nf-kb gene expression Download PDFInfo
- Publication number
- WO2012004653A1 WO2012004653A1 PCT/IB2011/001580 IB2011001580W WO2012004653A1 WO 2012004653 A1 WO2012004653 A1 WO 2012004653A1 IB 2011001580 W IB2011001580 W IB 2011001580W WO 2012004653 A1 WO2012004653 A1 WO 2012004653A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- daidzein
- daidzin
- palmitate
- cells
- gene expression
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a method of inhibition of synthesis of NF- ⁇ by inhibiting its gene expression using plant based isoflavones Daidzein and Daidzin derived from soybean (Glycine max) plant.
- NF-KB is a well known transcription factor that plays a critical role in inflammatory diseases including diabetes and cancer.
- NF- ⁇ remains as an inactive heterodimer having two polypeptide chains i.e. p50 and p65.
- the nuclear localisation signal domains of these two dimers remain blocked by another protein known as inhibitor of kappa B ( ⁇ ).
- ⁇ inhibitor of kappa B
- IKK inhibitor of kappa B kinase
- IKK inhibitor of kappa B kinase
- NF-KB regulates plethora of gene expression and many of them are related to diabetes, cancer, arthritis and Alzheimer's diseases.
- NF- ⁇ inhibitors there are some NF- ⁇ inhibitors available in the market and almost all of them are highly toxic and therefore cannot be used for therapeutic purpose. However all of these are activation inhibitors i.e. either it inhibits ⁇ or IKK phosphorylation.
- activation inhibitors i.e. either it inhibits ⁇ or IKK phosphorylation.
- honokiol obtained from Magnolia officinalis inhibits NF- ⁇ activation and downregulates NF-DB induced expression of gene products (Tse, A.K., Wan, C.K., Zhu, G.Y., Shen, X.L., Cheung, H.Y, Yang, M. and Fong, W.F.
- NF- ⁇ inhibitors There are many known NF- ⁇ inhibitors; they inhibit NF- ⁇ activation.
- Daidzein a non toxic isoflavone having molecular weight of 254, usually present in number of dietary supplements such as soybeans, legumes and peas. Daidzein inhibits NF- ⁇ gene expression that results in inhibition of protein expression and therefore, can be utilized for treating the various critical diseases, such as diabetes, cancer etc.
- NF- ⁇ is a transcription factor which was discovered by David Baltimore (Sen, R. and Baltimore, D (1986) Inducibility of k immunoglobulin enhancer- binding protein NF-kB by a post translational mechanism. Cell 47, 921-928.
- lipid induced overexpression of NF- ⁇ in skeletal muscle cells is related to insulin resistance (Barma, P., Bhattacharya, S., Bhattacharya, A., Kundu, R., Dasgupta, S., Biswas, A., Bhattacharya, S., Roy, S.S. and Bhattacharya, S. (2009) Lipid induced overexpression of NF- ⁇ in skeletal muscle cells is linked to insulin resistance. Biochim. Biophys. Acta. 1792, 190-200). Daidzein ameliorates palmitate induced overexpression of NF- ⁇ in skeletal muscle cells.
- isoflavone as drug candidate are glucuronidated in intestine and liver, and excreted out of the body through the urine and faecal matter.
- Absorption of daidzein poses a real problem to act as a drug because it has great limitation for bioavailability.
- Oral administration of daidzein does not lead to its availability in the serum suggesting its elimination from the gut through glucuronidation process due to the presence of UGT1 enzyme released from the gut cells (Hosoda, K., Furuta, T., Yokokawa, A., Ogura, K., Hiratsuka, A. and Ishii, K (2008).
- daidzein could effectively blocked NF- ⁇ transcription, since its absorption through the gut is a problem, its action on target tissue for inhibiting NF- ⁇ synthesis will not be effective to treat diseases where NF- ⁇ is involved.
- daidzin which is glucosylated and that could protect it from UGT1 mediated degradation.
- Fetuin-A K2-Heremans Schmid glycoprotein [Ahsg]
- an endogenous inhibitor of insulin receptor tyrosine kinase phosphorylation abrogates insulin stimulated downstream signals
- Auberger, P., Falquerho, L Confreres, J.O., Pages, G., Le Cam, G., Rossi, B. and Le Cam, A. (1989) Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity.
- NF-KB S ' IRNA inhibits the palmitate induced fetuin-A overexpression whereas in forced expression of NF- ⁇ in hepatocytes induces fetuin-A expression in absence of palmitate.
- Daidzein also inhibits fetuin-A protein and gene expression as it down regulation of NF- ⁇ synthesis.
- NF- ⁇ and fetuin-A is related to insulin resistance and type 2 diabetes, inhibition of NF- ⁇ transcription by daidzein helps in amelioration of insulin action.
- Daidzein increases insulin stimulated glucose uptake, as it helps in insulin stimulated Glut-4 migration towards the plasma membrane, which is downregulated by palmitate.
- NF-KB activity is increased in different types of cancers.
- PC-3 prostate cancer cell line
- MCF-7 breast cancer cell line
- the main objective of the present investigation is to provide a method of inhibition of synthesis of NF- ⁇ by inhibiting its gene expression using plant based molecules Daidzein and Daidzin.
- Another objective of the present investigation is to provide a therapeutic active compound that will inhibit NF- ⁇ transcription thus abrogate NF- ⁇ gene expression which will give another alternative to treat critical diseases like diabetes, cancer etc.
- the present invention provides a method for inhibiting NF- kappaB gene expression which comprises administering to a vertebrate in need of treatment, a therapeutically effective amount of atleast one compound selected from the group consisting of isoflavone obtainable from a soyabean plant belonging to the genus Glycine, and pharmaceutically acceptable salts thereof.
- a method for inhibiting NF- kappaB gene expression which comprises administering to a vertebrate in need of treatment, a therapeutically effective amount of atleast one compound selected from the group consisting of isoflavone obtainable from a soyabean plant belonging to the genus Glycine, and pharmaceutically acceptable salts thereof.
- isoflavone selected are daidzein and daidzin extracted from soybean.
- the cell lines used were selected from the group consisting of PC-3 Prostrate Cancer cell line, and MCF-7 Breast Cancer cell line.
- the NF-KappaB inhibition is used to treat diseases selected from the group comprising of Breast Cancer, Prostate Cancer and Diabetes.
- the effective amount of Daidzein used is about 3-5 g /ml.
- a method of treating human Prostrate cancer, Breast cancer, and Diabetes comprising administering orally to a subject in need thereof isoflavone selected from the group consisting of Diadzein and Diadzinin the range of 3-5 g /ml.
- Figure 1 represents standard HPLC peak of daidzein.
- Figure 2 represents standard HPLC peak of daidzin
- Figure 3 represents that the oral administration of daidzin increases bioavailability of daidzein (Dn).
- Dn bioavailability of daidzein
- Figure 4 represents Palmitate overexpresses NF-kB. Skeletal muscle cells were incubated with 0.75 rtiM palmitate for 4h in the presence insulin (100 nmole) and insulin stimulated [ 3 H] 2- deoxy-glucose uptake was determined (Fig.4A). L6 myotubes were transfected with GFP-Glut4 plasmid followed by incubation with palmitate or palmitate plus daidzein; insulin was added prior to 30 minutes of termination of incubation.
- Glut-4 translocation was observed under confocal microscope.
- FIG. 4 B Western blot was performed with palmitate incubated myotubes using anti-pNF-kBp65, NF-kBp65, pNF-kBp50 and NF-kBp50 antibodies.b-actin was used as loading control
- FIG. 4C Western blot was performed to determine NF-kB protein levels in a time and dose dependent manner (Fig.4D,E).Means ⁇ SEM was calculated from five independent experiments; * (p ⁇ 0.001 , #p ⁇ .01) as compared with the control and palmitate.
- Figure 5 represents that both Daidzein(Dn) and daidzin(Din) inhibits NF-kB protein and gene expression.
- Skeletal muscle cells were incubated with palmitate in the presence or absence of daidzein.
- Changes in the NF-kB p65 and NF-kBp50 protein level was determined through immunoblot using NF- kB p65 or NF-kB p50 antibodies, ⁇ actin was used as a loading control (Fig.5A).
- Skeletal muscle cells were incubated for 4h with insulin or palmitate or palmitate plus daidzein or without any of them (C- control).
- Figure 6 represents purification of NF-kb p65 protein.
- Control and palmitate incubated (6h) L6 skeletal muscle cell lysates were resolved on a 10% SDS-PAGE. A clear solid band at the 65 kDa region indicates overexpression of NF- kB p65 protein.
- L6 skeletal muscle cells were incubated with palmitate and cell lysates after centrifugation was loaded on a Sephadex G-75 column. A control was run parallely to see any expression of NF- kB protein due to palmitate incubation. Separately collected fractions (such as A1, A2 and A3) from control and palmitate treated cell lysates were immunoblotted with anti-NF- kB p65 antibody.
- the lanes A1 and A2 shows the immunoreactive bands of NF- kB "
- the pooled fractions from gel filtration chromatography was lyophilized and loaded on a CNBr activated Sepharose 4Bimmunoaffinity column P1 (unbound protein) and P2 (bound fraction after elution with 2M Kl) peaks were collected and Western blot analysis shows P2 as immunoreactive band of NF- kB
- FIG.7A NF-kBp65 protein was delivered in L6 skeletal muscle cells and its incorporation was detected by immunofluorescence. NPT transducted cells were incubated with daidzein [ 3 H] 2-deoxyglucose uptake was determined (Fig.7A). Control and NF-kBp65 transducted cells (NPT) were subjected to Western blot analysis with anti-NF- kB p65 antibody (Fig.7B).
- C) GFP-Glut 4 construct was transfected into the skeletal muscle cells and incubated with insulin (I) or l+NF-kBp65 protein or l+NF- kBp65 protein+daidzein or with none (C-control). On termination of incubation, GFP- Glut 4 localization was detected by using laser scanning confocal microscope. (Fig.7C) Values represent means ⁇ SEM of three independent experiments, *p ⁇ 0.01 (I vs I + NPT).
- Figure 8 Increase of NF- kB nuclear localization is inhibited by daidzein.
- L6myotubes were incubated with palmitate or palmitate+daidzein. Immunofluorescence study was performed under fluorescence microscope.
- Figure 9 represents the relationship between NF- kB overexpression and activation.
- Nuclear extracts (NE) were prepared from L6 skeletal muscle cells incubated for 4h with palmitate, palmitate plus daidzein or SN50 or without any of them (control) followed by EMSA. Both wild type and mutant DNA sequences were used to determine the specificity of NF- kB binding (Fig.9A).
- FIG. 10 Palmitate stimulation of NF- kB expression is inhibited by daidzein (Dn).
- Dn daidzein
- NF- kB cis-reporter gene plasmid transfected L6 myotubes were incubated with palmitate (P) and palmitate+Dn. Luciferase activity was determined after 5h of incubation. Prior to palmitate incubation cells were pre-incubated for 1 h with Dn.
- FIG. 10A Means ⁇ SEM was calculated from three independent experiments Myotubes incubated with(P) or without(C) palmitate and palmitate+Dn were subjected to FACS analysis using anti-NF- ⁇ specific antibodies (Fig. 10B).
- FIG11 NF-kB mediated fetuin-A expression is inhibited by daidzein (Dn).
- Dn daidzein
- Hepatocytes were incubated without (Ctl) or with 0.75 mM palmitate (P) for 4h.
- Prior to palmitate incubation cells were pre-incubated for 1 h with Dn.
- siRNA transfected cells were incubated with daidzein.
- Cells were lysed and immunoblotted with anti-Fetuin-A antibody. ⁇ actin served as internal control.
- RNA extracted from the above incubations was subjected to RT-PCR and Real time PCR using Fetuin-A specific primers where gapdh served as internal control. Means ⁇ SEM was calculated from three independent experiments.
- Figure 12 Daidzein has protective effect against prostate cancer and breast cancer.
- PC-3 and MCF-7 cells were incubated with daidzein at a concentration of 5 ⁇ g/ml. Cell mortality was determined under microscope.
- RNA extracted from the above incubations was subjected to RT-PCR using NF-kB specific primers where gapdh served as internal control. Means ⁇ SEM was calculated from three independent experiments (Fig. 12A&B).
- Figure 13 Relationship between expression and activation of NF- kB p65 in MCF-7 and PC-3 cells MCF-7 and PC-3 cells were treated without (Con) or with Dn ( ⁇ / ⁇ ) or transfected with NF- kB p65 siRNA (p65KO) or scramble siRNA (Mock).
- Control cells contained DMSO as vehicle. Total RNA extracted from these cells was subjected to qPCR analysis using NF- kB p65 gene specific primers, gapdh was used as kB internal control. MCF-7 and PC-3 cells were incubated without or with Dn or transfected with NF- kB p65 (p65KO) or scramble (Mock) siRNA followed by the incubation of [ 3 H]-leucine or [ ⁇ 32 ⁇ ]- ⁇ .
- NF- kB p65 or pNF- kB p65 was pull-down from the cell lysates and % incorporation of radiolabelled leucine or phosphate into NF- kB p65 or pNF- kB p65 was determined by radioactive counting in liquid scintillation counter.
- Figures are one of the representatives of five individual experiments. Data represented are means ⁇ SEM, *p ⁇ 0.01 vs Con, #p ⁇ 0.001 vs Con.
- Figure 14 Daidzein and daidzin inhibits cell survivability MTT assay was performed in a dose dependent manner with daidzein and daidzin in a dose dependent manner.
- Daidzein a non toxic dietary supplement isoflavone of the structure 1, is a novel inhibitor of NF- ⁇ which blocks the synthesis of NF- ⁇ by inhibiting its gene expression.
- Daidzein of the structure ⁇ inhibits NF- ⁇ gene transcription but had no toxic effect.
- Daidzin, glucopyranosyl daidzein of the sturucture 2 is also an inhibitor of NF-KB which blocks the synthesis of NF- kB by inhibiting its gene expression and has no toxic effect.
- Both daidzein of the structure ⁇ and daidzin of the structure 2 ameliorate palmitate induced overexpression of NF- ⁇ in skeletal muscle cells.
- Daidzein of the structure 1 and daidzin of the structure 2 increase insulin stimulated glucose uptake, as it helps in insulin stimulated Glut-4 migration towards the plasma membrane, which is downregulated by palmitate.
- Both daidzein of the structure i and daidzin of the structure 2 are inhibitors of PC-3 (prostate cancer cell line) and MCF-7 (breast cancer cell line) cells and are novel NF- ⁇ transcription inhibitor.
- Daidzin of the structure 2 has very good bioavailibility over daidzein. Daidzein is present in dietary supplements, it is found in soyabeans, legumes and peas but it poses a problem of bioavailability.
- Daidzein of the structure 1 is not absorbed when orally fed to mice as it is eliminated from the gut through glucuronidation process due to the presence of UGT1 enzyme released from the gut cells.
- Daidzin of the structure 2 is glucosylated daidzein and is protected from UGT1 mediated degradation and is hydrolysed to daidzein which is absorbed and remains for more than 4 hours in blood therefore expected to be distributed to different tissues and organs.
- Daidzein of the structure 1 and daidzin of the structure 2 reduce palmitate stimulated increased synthesis of NFKB significantly.
- Daidzein inhibits formation of NF- ⁇ -DNA complex stimulated by palmitate.
- daidzein of the structure 1_and daidzin of the structure 2 have protective effect against prostate cancer and breast cancer by inhibiting the gene expression of NF-KB in PC-3, breast cancer. These two compounds are also therapeutically active by inhibiting NF- kB transcription which would be beneficial for treating critical diseases like diabetes, arthritis and Alzheimer's diseases etc.
- Daidzein of the structure 1_ and daidzin of the structure 2 were obtained from soy leaves through chromatography and both natural and commercial/synthetic daidzein and daidzin have same biological activities.
- the following examples are given by way of illustration and should not be construed to limit the scope of present invention.
- Daidzin an isoflavone was isolated and purified from Glycine max leaves through solvent fractionations, Diaion HP-20 and m-Bonadapak C-18 reverse phase column chromatography. Its structure was determined by 1 H NMR, 13 C NMR and Q-TOF-MS.
- the plant material of 100 g of fresh leaves was crushed in a mixer-cum-grinder and immersed in 200 ml of ethanol/water (70/30, v/v) overnight.
- the extract was obtained after filtration and the plant material was immersed again in raw ethanolic 200 ml of ethanol/water (70/30, v/v) overnight. The process is repeated three times.
- the combined extract was concentrated under reduced pressure at below 50°C.
- the concentrated extract was then defatted by extracting with hexane (100 ml x 3).
- the defatted aquous layer was then extracted with chloroform followed by ethyl acetate.
- the ethyl acetate layer was dried over anhydrous sodium sulphate and then distilled under reduced pressure at below 50°C.
- the gummy mass obtained was then chromatographed over a silica gel column using ethyl acetate, 50% methanolic ethyl acetate, methanol and 45% water in methanol. Fractions obtained by elution of 45% water in methanol were found to be daidzein and daidzin respectively.
- Bioavailibility Bioavalability of daidzein and daidzin was tested by oral feeding of a solution of daidzein and daidzin to mice and collecting blood at 15 minutes, 30 minutes, 60 minutes, 120 minutes and 240 minutes followed by separation of serum. At first a standard curve was calibrated for HPLC estimation of daidzein and daidzin in blood by using standard and authenticated daidzein and daidzin. Later, we purified daidzein from soybean seeds by using authenticated daidzein as the standard. Analysis of daidzein was performed with Waters HPLC equipment using Zorbax C18 45 column.
- the blood serum collected after 15 minutes of feeding showed a peak at retention time 5.227 minute indicating clearly that daidzin was not in the blood and daidzein, the hydrolyzed product of the isoflavone glycoside daidzin, was present in the blood serum.
- the hydrolyzed product of daidzin was observed for the serum sample collected at 4 hours, this shows that daidzein is available from circulatory source by the respective tissues and organs of the body for at least 4 hours which is an appreciable retention time in blood serum.
- Daidzein Since bioavalability of flavone compounds is a problem because of their rapid elimination through the intestine due to glucuronidation by UGT groups of enzymes (King R. (1998) Am. J. Clin. Nutr. 68, 1496S-1499S), we examined the same for Daidzein.
- Daidzein has two naturally available forms, one is glycosylated (daidzin) and another aglycone (daidzein), we have used daidzein in our experiments as it is comparatively more active. However, its absorption through the intestine is less than daidzin.
- NF- ⁇ is a transcription factor that not only regulates diabetes but it is related to most of the inflammatory diseases like cancer, arthritis and Alzheimer's disease. Therefore there is a need to find out a potent inhibitor of NF- ⁇ .
- daidzin a isoflavone glycoside from soyabean leaves
- intestinal cells it is hydrolysed to form daidzein.
- daidzin and daidzein can efficiently inhibit NF- ⁇ gene transcription and protein synthesis.
- Soy isoflavones daidzein and genistein are currently being investigated in clinical studies.
- Daidzein does not share these side effects and is more effective. Daidzein is present in dietary supplements, it is found in soyabeans, legumes and peas but it poses a problem of bioavailability. This problem could be avoided by using daidzin.
- L6 skeletal muscle cell line To monitor inhibition of NF- ⁇ expression we have used L6 skeletal muscle cell line and conducted the assays where insulin activity is inhibited by NF- ⁇ . It is well-known that NF-KB inhibits insulin activity. L6 myotubes or skeletal muscle cell were incubated with or without palmitate or palmitate plus daidzein.lOOnM insulin and [ 3 H2-DOG] were added to these incubations before termination of incubation of cells. Insulin stimulated glucose uptake was significantly reduced by palmitate while daidzein co-incubation strikingly reduced palmitate adverse effect (Fig. 4 A).
- L6 myotubes were incubated without or with palmitate, lysed by ultrasonication and then centrifuged. The supernatant was collected and loaded on Sephadex G75 column. The elution profile from these cells showed an increase of NF- ⁇ p65 protein due to palmitate (A2) treatment in comparison to control (A1 ).
- the eluted fractions from these incubations were subjected to immunoaffinity chromatography by anti-NF- ⁇ 65 antibody for further purification.
- the eluted fraction (P2) from immunoaffinity chromatography shows the cross reactivity with anti-NF- ⁇ antibody in Western blot analysis (Fig.6).
- palmitate induced increased synthesis of NF-KB was prevented by daidzein.
- NF- ⁇ p65 protein was transducted to L6 skeletal muscle cells and then subjected to insulin incubation.
- Palmitate activation leads to the increase in NF- ⁇ nuclear localization.
- NF-KB in skeletal muscle cells by immunofluorescence study using FITC conjugated anti-NF- ⁇ p65 antibody. Palmitate enhanced NF- ⁇ level both in the cytoplasm and nuclear region was inhibited by daidzein (Fig.8).
- Daidzein inhibits palmitate induced NF- ⁇ promoter activity.
- Cells were incubated without (control) or without palmitate and palmitate plus daidzein.
- NF- ⁇ promoter activity increased remarkably due to palmitate incubation and daidzein reduces the palmitate stimulatory effect (Fig.10 A).
- Fig.10 B Flow cytometric analysis showed that increased level of NF- ⁇ in response to palmitate was significantly inhibited by daidzein (Fig.10 B).
- NF-KB regulates transcription of many inflammatory genes. It regulates transcription of fetuin-A, an inhibitor of insulin receptor tyrosine kinase.
- Primary hepatocytes were incubated without or with palmitate or palmitate plus daidzein. Palmitate significantly induced fetuin-A gene expression.
- Addition of NF- ⁇ siRNA or Daidzein inhibits fetuin-A synthesis by inhibiting NF- ⁇ expression (Fig. 11 ). By preventing NF- ⁇ gene expression daidzein can modulate NF- ⁇ downstream signalling.
- Daidzein has also protective effect against prostate cancer and breast cancer. Daidzein at concentration of 5 g/ml reduce the gene expression of NF- ⁇ in PC-3, androgen independent prostate cancer cell line (Fig.12 A) and MCF-7, breast cancer cell line (Fig.12 B).
- tissue culture materials were obtained from Gibco-BRL, Life Technologies Inc., Gaithersburg, USA.
- [ 3 H]-leucine (specific activity 1000 Ci/mmol), was obtained from GE Healthcare, Kowloon, Hong Kong.
- [ ⁇ - 32 ⁇ ]- ⁇ (Specific activity: 6000 Ci/mmol) was procured from BRIT, India.
- the primary antibodies for NF-kBp65, pNF-kBp65, ⁇ / ⁇ , ⁇ , and ⁇ -actin were purchased from Santa Cruz Biotechnology Inc., California, USA.
- Control and NF-kBp65 (h) siRNA were also purchased from Santa Cruz Biotechnology Inc., California, USA.
- Fluorescence iso-thiocyanate (FITC) conjugated goat anti-rabbit and alkaline phosphatase conjugated secondary antibodies were purchased from Sigma Chemical Co., St. Louis MO, USA. All other chemicals and reagents were purchased from Sigma Chemical Co., St. Louis MO, USA.
- the breast cancer cell line MCF-7 the prostate cancer cell line PC-3 and L-6 skeletal muscle cell line were gifted by Dr. Partha P. Banerjee, Georgetown University Medical Center, USA (ATCC Deposit No.MCF-7, HTB-22, PC-3 CRL-1435, L6-CRL- 1458.). These cells were cultured in DMEM containing Earle's salts and non-essential amino acids supplemented with 10% fetal calf serum, penicillin (100 U/ml) and streptomycin (100 pg/ ml) in a humidified 95% 0 2 /5% C0 2 atmosphere at 37°C. 3. Cell culture treatments
- Confluent cells were subcultured by trypsinization and subsequently seeded in six well culture plates containing DMEM with essential supplements.
- Confluent MCF-7 cells were incubated with 3Dg/ml daidzein (Dn) and PC3 cells were incubated with 5 ⁇ g/ml daidzein. Daidzein was dissolved in DMSO.
- Control cells were treated with equal amounts of DMSO in the media. At the end of incubation, cells were lysed, centrifuged for 10 min at 10,000g and the supernatant was collected. Protein concentration of supernatant was determined by following the method of Lowry et al [O.H. Lowry, N.J. Rosebrough, A.E. Farr, R.J.
- the membranes were first incubated with different primary antibodies at 1 :1000 dilutions followed by respective alkaline phosphatase conjugated secondary antibodies at same dilutions using SNAP i.d. apparatus (Millipore, Bedford, MA).
- the protein bands were detected by developing with 5-bromro 4-chloro 3-indolyl phosphate/nitroblue tetrazolium (BCIP/NBT).
- RT-PCR was performed with First strand cDNA synthesis kit, Fermentas Life Sciences, Revert AidTM, Hanover, MD, USA. Relative gene expression was further confirmed by Real-time PCR (Applied Biosystems Inc. CA, USA). PCR was performed using gene specific primers in the following reaction conditions: initial activation step at 95°C for 15mins, denaturation at 95°C for 30s, annealing at 50-55°C for 30s and final extension at 72°C for 30s x 40 cycles, gapdh was simultaneously amplified in separate reactions. C T value was corrected using corresponding gapdh controls.
- NF-kBp65 forward: 5'-ccatcagggcagatctcaaacc-3' reverse: 5'-gctgctgaaactctgagttgtc-3'; Gene bank accession no. NM_021975.3
- Bcl-2 forward: 5'-TGGGATGCCTTTGTGGAACT- 3', reverse: 5'-GAGACAGCCAGGAGAAATCAAAC-3'; Gene bank accession no. NM_000657.1
- Cyclin D1 forward: 5 -GGATGCTGGAGGTCTGCGAGGAAC-3', reverse: 5 -GAGA-GGAAGCGTGTGAGGCGGTAG-3'; Gene bank accession no.
- gapdh forward: 5'-gccatcaacgaccccttc-3', reverse: 5'- agccccagccttctcca-3'; Gene bank accession no. J04038.1 ).
- NF-kB rich fraction gel filtration chromatography was performed on a Sephadex G-75 (Amersham Pharmacia Biotech AB, Uppsala, Sweden) column (2x50 cm) equilibrated with Tris-CI buffer (10 mM Tris-CI, pH-7.4) by following an earlier description from this laboratory [D. Basu, S. Bhattacharya, Purification of two types of gonadotropin receptors from carp ovarian follicles: overlapping recognition by two different ligands, Gen. Comp. Endo. 129 (2002) 152-162]. The flow rate was maintained at 1 ml/min and 1.0 ml fractions were collected just after loading the skeletal muscle cell lysate.
- Unbound antibody was removed by washing with coupling buffer (pH-8.5) followed by acetate buffer (0.1 M, pH-4.0). The remaining active groups on the beads were blocked with glycine buffer (0.2 M, pH-8.0). The sample was loaded on the column and kept overnight at 4°C. The unbound proteins were eluted with 10 mM Tris- HCI buffer, pH-7.4 while NF-kBp65 bound to the ligand was eluted with elution buffer (10 mM Tris-HCI, pH -7.4) containing 2.0 M Kl as a chaotropic agent. The volume of each eluted fraction was 1.0 ml. The fractions were collected until the O.D.
- NF-kB p65 was examined in a 10% SDS-PAGE where it gave a single protein band which also crossreacted with anti-NF-kB p65 antibody.
- EMSA was performed by using nuclear extracts prepared from different incubations in cancer cells using oligonucleotide probes specific for NF-kB binding site (Wild: 5 - AGTTGAGGGGACTTTCCCAGGC -3', mutants: 5'- AGTTGAGGGAACTTTCCCAGGC -3', AGTTGAGGAAACTTTCCCAGGC -3').
- the probes were end-labelled with [ ⁇ 32 ⁇ ]- ⁇ using T4 polynucleotide kinase and then incubated with 10 Dg of nuclear extracts of control and Dn treated MCF-7 and PC3 cells in a 20 Dl of binding reaction for 45 min. Reaction mixtures were resolved on 5% polyacrylamide gel and visualized by Phosphorlmager (GE Healthcare, USA).
- MCF-7 and PC3 cells were incubated in Kreb's Ringer Phosphate (KRP) buffer supplemented with 0.2% bovine serum albumin.
- KRP Kreb's Ringer Phosphate
- cells were incubated with 10 ⁇ / ⁇ of [ 3 H]-leucine in the presence or absence of Dn.
- Cells were also transfected with NF-kBp65 siRNA or scramble siRNA.
- NF-kBp65 was pulled down by anti-NF-kBp65 antibody. Radioactive count incorporation to NF-kBp65 was measured in Liquid Scintillation counter (Perkin Elmer, Tri-Carb 2800TR).
- MCF-7 and PC3 cells were incubated without or with daidzein (Dn) or transfected with NF-kBp65 siRNA or scramble siRNA in the presence of 80 ⁇ [ ⁇ 3 ⁇ ]- ⁇ and on termination of incubation, cell lysates were subjected to immunoprecipitation with anti- pNF-kBp65 antibody. Radioactive count incorporation to pNF-kBp65 was measured in Liquid Scintillation counter (Perkin Elmer, Tri-Carb 2800TR).
- MCF-7 and PC3 cells were treated without (Con) or with Dn (3 and 5 dg/ml repectively) or transfected with NF- kB p65 siRNA (p65KO) or scramble siRNA (Mock).
- Control cells contained DMSO as vehicle. Total RNA extracted from these cells was subjected to qPCR analysis using NF-i Bp65 gene specific primers, gapdh was used as internal control.
- MCF-7 and PC3 cells were incubated without or with Dn or transfected with NF- kB p65 (p65KO) or scramble (Mock) siRNA followed by the incubation of [ 3 H]-leucine or [ ⁇ 32 ⁇ ]- ⁇ .
- NF- kB p65 or pNF- kB p65 was pull-down from the cell lysates and % incorporation of radiolabelled leucine or phosphate into NF- kB p65 or pNF- kB p65 was determined by radioactive counting in liquid scintillation counter.
- Figures are one of the representatives of five individual experiments. Data represented are means ⁇ SEM, *p ⁇ 0.01 vs Con, #p ⁇ 0.001 vs Con.
- Our results demonstrate that suppression of NF- kB p65 gene expression by p65siRNA and a flavone compound; daidzein (Dn) reduced both inactive and phosphorylated form of NF- kB in cancer cells.
- NF- kB p65 siRNA specifically inhibits its mRNA whereas Dn occupies promoter kB segment where NF- kB binds to express its gene.
- Dn occupies promoter kB segment where NF- kB binds to express its gene.
- NF- kB protein synthesis was markedly reduced because of suppressed NF- kB gene expression by NF-KBp65 siRNA or Dn. This corresponded with the significant decline of phosphorylated NF- kB indicating that active NF- kB pool in these cells is dependent on its de novo synthesis.
- Daidzein inhibits NF-kB synthesis by reducing its gene expression.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11746612.8A EP2590646A1 (en) | 2010-07-07 | 2011-07-07 | Method for inhibition of nf-kb gene expression |
JP2013517575A JP2013530207A (en) | 2010-07-07 | 2011-07-07 | Method for inhibiting NF-κB gene expression |
AU2011275442A AU2011275442A1 (en) | 2010-07-07 | 2011-07-07 | Method for inhibition of NF-kB gene expression |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1590DE2010 | 2010-07-07 | ||
IN1590/DEL/2010 | 2010-07-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012004653A1 true WO2012004653A1 (en) | 2012-01-12 |
WO2012004653A8 WO2012004653A8 (en) | 2012-12-20 |
Family
ID=44503999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2011/001580 WO2012004653A1 (en) | 2010-07-07 | 2011-07-07 | Method for inhibition of nf-kb gene expression |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2590646A1 (en) |
JP (1) | JP2013530207A (en) |
AU (1) | AU2011275442A1 (en) |
WO (1) | WO2012004653A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993023069A1 (en) * | 1992-05-19 | 1993-11-25 | Graham Edmund Kelly | Health supplements containing phyto-oestrogens, analogues or metabolites thereof |
EP1127572A2 (en) * | 2000-02-25 | 2001-08-29 | Basf Aktiengesellschaft | Use of flavones for treating cycloxygenase-2 mediated diseases |
JP2003286166A (en) * | 2002-03-26 | 2003-10-07 | Nichimo Co Ltd | Preparation for prevention and treatment of insulin- resistant diabetes |
JP2004196720A (en) * | 2002-12-19 | 2004-07-15 | Nichimo Co Ltd | Prophylactic/therapeutic preparation for prostatic disease |
-
2011
- 2011-07-07 JP JP2013517575A patent/JP2013530207A/en not_active Withdrawn
- 2011-07-07 WO PCT/IB2011/001580 patent/WO2012004653A1/en active Application Filing
- 2011-07-07 AU AU2011275442A patent/AU2011275442A1/en not_active Abandoned
- 2011-07-07 EP EP11746612.8A patent/EP2590646A1/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993023069A1 (en) * | 1992-05-19 | 1993-11-25 | Graham Edmund Kelly | Health supplements containing phyto-oestrogens, analogues or metabolites thereof |
EP1127572A2 (en) * | 2000-02-25 | 2001-08-29 | Basf Aktiengesellschaft | Use of flavones for treating cycloxygenase-2 mediated diseases |
JP2003286166A (en) * | 2002-03-26 | 2003-10-07 | Nichimo Co Ltd | Preparation for prevention and treatment of insulin- resistant diabetes |
JP2004196720A (en) * | 2002-12-19 | 2004-07-15 | Nichimo Co Ltd | Prophylactic/therapeutic preparation for prostatic disease |
Non-Patent Citations (26)
Title |
---|
ALONSO V ET AL: "Phytoestrogen modulation of bone-related cytokines and its impact on cell viability in human prostate cancer cells", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 85, no. 11-12, 9 September 2009 (2009-09-09), pages 421 - 430, XP026564270, ISSN: 0024-3205, [retrieved on 20090723], DOI: 10.1016/J.LFS.2009.07.005 * |
AUBERGER, P., FALQUERHO, L., CONTRERES, J.O., PAGES, G., LE CAM, G., ROSSI, B., LE CAM, A.: "Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA doning, purification, and anti-mitogenic activity", CELL, vol. 58, 1989, pages 631 - 640 |
BARMA, P., BHATTACHARYA, S., BHATTACHARYA, A., KUNDU, R., DASGUPTA, S., BISWAS, A., BHATTACHARYA, S., ROY, S.S., BHATTACHARYA, S.: "Lipid induced overexpression of NF-KB in skeletal muscle cells is linked to insulin resistance", BIOCHIM. BIOPHYS. ACTA, vol. 1792, 2009, pages 190 - 200, XP026003733, DOI: doi:10.1016/j.bbadis.2008.11.014 |
CAI, D., YUAN, M., FRANTZ, D.F., MELENDEZ, P.A., HANSEN, L., LEE, J., SHOELSON, S.E.: "Local and systemic insulin resistance resulting from hepatic activation of IKK-(3 and NF-KB", NAT. MED., vol. 11, 2005, pages 183 - 190, XP009150608, DOI: doi:10.1038/nm1166 |
CHOI EUN JEONG ET AL: "Daidzein causes cell cycle arrest at the G1 and G2/M phases in human breast cancer MCF-7 and MDA-MB-453 cells", PHYTOMEDICINE (JENA), vol. 15, no. 9, September 2008 (2008-09-01), pages 683 - 690, XP002664511, ISSN: 0944-7113 * |
D. BASU, S. BHATTACHARYA: "Purification of two types of gonadotropin receptors from carp ovarian follicles: overlapping recognition by two different ligands", GEN. COMP. ENDO., vol. 129, 2002, pages 152 - 162 |
DATABASE WPI Week 200382, Derwent World Patents Index; AN 2003-885516, XP002664509 * |
DATABASE WPI Week 200449, Derwent World Patents Index; AN 2004-513205, XP002664508 * |
HOSODA, K., FURUTA, T., YOKOKAWA, A., OGURA, K., HIRATSUKA, A., ISHII, K: "Plasma profiling of intact isoflavone metabolites by high-performance liquid chromatography and mass spectrometric identification of flavone glycosides daidzin and genistin in human plasma after administration of kinako", DRUG METABOLISM AND DISPOSITION, vol. 36, 2008, pages 1485 - 1495 |
JIN S ET AL: "Daidzein induces MCF-7 breast cancer cell apoptosis via the mitochondrial pathway.", ANNALS OF ONCOLOGY : OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY / ESMO FEB 2010 LNKD- PUBMED:19889614, vol. 21, no. 2, February 2010 (2010-02-01), pages 263 - 268, XP002664510, ISSN: 1569-8041 * |
KARIEB SAHAR ET AL: "Phytoestrogens Directly Inhibit INF-alpha-Induced Bone Resorption in RAW264.7 Cells by Suppressing c-fos-Induced NFATc1 Expression", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 112, no. 2, February 2011 (2011-02-01), pages 476 - 487, XP002664513 * |
KIM, D.J., SEOK, S.H., BAEK, M.W., LEE, H.Y., NA, Y.R., PARK, S.H., LEE, H.K., DUTTA, N.K., KAWAKAMI, K., PARK, J.H.: "Developmental toxicity and brain aromatase induction by high genistein concentrations in zebrafish embryos", TOXICOLOGY MECHANISMS AND METHODS, vol. 19, 2009, pages 251 - 256 |
KING R., AM. J. CLIN. NUTR., vol. 68, 1998, pages 1496S - 1499S |
KING, R., BURSILL, D.B., AM. J. CLIN. NUTR., vol. 67, 1998, pages 862 - 872 |
O.H. LOWRY, N.J. ROSEBROUGH, A.E. FARR, R.J. RANDALL: "Protein measurement with Folin phenol reagent", J. BIOL. CHEM., vol. 193, 1951, pages 265 - 275, XP000196391 |
RAUTH, G., POSCHKE, O., FINK, E., EULITZ, M., TIPPMER, S., KELLERER, M., HARING, H.U., NAWRATIL, P., HAASEMANN, M., JAHNEN-DECHENT: "The nucleotide and partial amino acid sequences of rat fetuin: Identity with the natural tyrosine kinase inhibitor of the rat insulin receptor", EUR. J. BIOCHEM., vol. 204, 1992, pages 523 - 529 |
S. DASGUPTA, S. BHATTACHARYA, A. BISWAS, S. S. MAJUMDAR, S. MUKHOPADHYAY, S. RAY, S. BHATTACHARYA: "NF-xB mediates lipid-induced fetuin-A expression in hepatocytes. that impairs adipocyte function effecting insulin resistance", BIOCHEM. J., vol. 429, 2010, pages 451 - 462 |
SAITOH ET AL., CANCER, vol. 70, 2010, pages 263 - 270 |
SEN, R., BALTIMORE, D: "Inducibility of k immunoglobulin enhancer- binding protein NF-kB by a post translational mechanism", CELL, vol. 47, 1986, pages 921 - 928 |
SHRECK, R., MEIER, B., MANNEL, D.N., DROGE, W., BAEUERIE, P.A.: "Dithiocarbamate as potent inhibitors of nuclear factor kappa B activation in intact cells", JEM, vol. 175, 1992, pages 1181 - 1194 |
SINGH AJITA V ET AL: "Soy phytochemicals prevent orthotopic growth and metastasis of bladder cancer in mice by alterations of cancer cell proliferation and apoptosis and tumor angiogenesis", CANCER RESEARCH, vol. 66, no. 3, February 2006 (2006-02-01), pages 1851 - 1858, XP002664512, ISSN: 0008-5472 * |
SINGH, H., SEN, R., BALTIMORE, D., SHARP, P.A.: "A nuclear factor that binds to a conserved sequence motif in transcriptional control elements of immunoglobulin genes", NATURE, vol. 319, 1986, pages 154 - 158, XP001084238, DOI: doi:10.1038/319154a0 |
TSE, A.K., WAN, C.K., ZHU, G.Y., SHEN, X.L., CHEUNG, H.Y, YANG, M., FONG, W.F.: "Magnolol suppresses NF-kappaB activation and NF-kappaB regulated gene expression through inhibition of IkappaB kinase activation", MOL. IMMUNOL., vol. 44, 2007, pages 2647 - 2658, XP005890540, DOI: doi:10.1016/j.molimm.2006.12.004 |
VALACHOVICOVA TATIANA ET AL: "Soy isoflavones suppress invasiveness of breast cancer cells by the inhibition of NF -. kappa .B/AP-1-dependent and -independent pathways", INTERNATIONAL JOURNAL OF ONCOLOGY, LYCHNIA, GR, vol. 25, no. 5, 1 January 2004 (2004-01-01), pages 1389 - 1395, XP008145541, ISSN: 1019-6439 * |
YU ET AL., INT J COLORECTAL DIS, vol. 19, 2004, pages 18 - 22 |
YU ET AL., ONCOLOGY, vol. 65, 2003, pages 37 - 45 |
Also Published As
Publication number | Publication date |
---|---|
AU2011275442A1 (en) | 2013-01-24 |
WO2012004653A8 (en) | 2012-12-20 |
EP2590646A1 (en) | 2013-05-15 |
JP2013530207A (en) | 2013-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lu et al. | Purple sweet potato color attenuates domoic acid-induced cognitive deficits by promoting estrogen receptor-α-mediated mitochondrial biogenesis signaling in mice | |
CN109310740B (en) | Composition for preventing or treating sarcopenia using SLIT-ROBO system | |
CN107921015B (en) | Azelaic acid composition with effect of hydrolyzing triglyceride in adipose tissue | |
Xu et al. | Enhanced cellular cholesterol efflux by naringenin is mediated through inhibiting endoplasmic reticulum stress-ATF6 activity in macrophages | |
Hu et al. | Senkyunolide I attenuates oxygen-glucose deprivation/reoxygenation-induced inflammation in microglial cells | |
AU2006231071B2 (en) | Tripeptides that down regulate the activity of plasma membrane transporters including sodium-D-glucose cotransporter SGLT1 | |
KR101653451B1 (en) | HER-2 targeted aptamer complex and use thereof | |
KR20190098649A (en) | Pharmaceutical composition containing cannabidiol extract for preventing or treating conlon cancer | |
Zhou et al. | Fenugreek attenuates obesity-induced inflammation and improves insulin resistance through downregulation of iRhom2/TACE | |
Mladenova et al. | Anti-adipogenic activity of maackiain and ononin is mediated via inhibition of PPARγ in human adipocytes | |
Majeed et al. | Garcinia indica extract standardized for 20% Garcinol reduces adipogenesis and high fat diet-induced obesity in mice by alleviating endoplasmic reticulum stress | |
Hsieh et al. | Cell suspension culture extract of Eriobotrya japonica attenuates growth and induces apoptosis in prostate cancer cells via targeting SREBP-1/FASN-driven metabolism and AR | |
Ahujaa et al. | Protium javanicum Burm. methanol extract attenuates LPS-induced inflammatory activities in macrophage-like RAW264. 7 cells | |
Chen et al. | Patchouli alcohol inhibits D-gal induced oxidative stress and ameliorates the quality of aging cartilage via activating the Nrf2/HO-1 pathway in mice | |
Xue et al. | A novel protoapigenone analog RY10-4 induces apoptosis of breast cancer cells by exacerbating mitochondrial Ca2+ influx through mitochondrial calcium uniporter | |
Xia et al. | Orientin inhibits inflammation in chondrocytes and attenuates osteoarthritis through Nrf2/NF‐κB and SIRT6/NF‐κB pathway | |
Han et al. | Ulmoidol, an unusual nortriterpenoid from Eucommia ulmoides Oliv. Leaves prevents neuroinflammation by targeting the PU. 1 transcriptional signaling pathway | |
JP2009503061A (en) | Glucosamine or a derivative thereof useful as a transglutaminase inhibitor | |
WO2020071795A1 (en) | Anticancer pharmaceutical composition containing if1 as active ingredient | |
WO2015093901A1 (en) | Pharmaceutical composition containing taz protein activation inducing component for muscle differentiation and muscle regeneration | |
Yang et al. | Use of the disulfiram/copper complex for breast cancer chemoprevention in MMTV‑erbB2 transgenic mice | |
KR100794610B1 (en) | Compositions for cancer chemoprevention and treatment containing dibenzo-p-dioxine derivatives and health supplementary foods containing the same | |
WO2012004653A1 (en) | Method for inhibition of nf-kb gene expression | |
US8519007B2 (en) | Use certain diterpene compounds in the treatment of androgen receptor-associated diseases | |
US10105414B2 (en) | Peptides derived from RS1 which down-regulate glucose absorption after a glucose rich meal and increase insulin sensitivity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11746612 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2011746612 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2013517575 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2011275442 Country of ref document: AU Date of ref document: 20110707 Kind code of ref document: A |